viewOrthocell Ltd

Orthocell at forefront of growing market opportunity in regenerative musculoskeletal treatment

The company’s portfolio of regenerative medicine products have shown in clinical studies and real world evidence to return patients to work, activities of daily living and elite sport pain-free.

Orthocell Ltd - Orthocell at the forefront of growing market opportunity in regenerative musculoskeletal medicine
Orthocell is focused on completing current clinical studies and preparing for Australian and US market entry

Orthocell Ltd (ASX:OCC) is confident that its unique regenerative medicine product portfolio can address growing market opportunities in the treatment of complex musculoskeletal disorders.

The company is pursuing a total addressable market for CelGro® and Ortho-ATI® of US$10 billion and US$7.7 billion respectively – representing a combined US$17.7 billion per annum.

This market is driven by the rising rate of musculoskeletal disorders and demand for efficient and cost-effective treatments.

CelGro® nerve repair

The company’s CellGro collagen medical device is designed to augment surgical repair of soft tissue and represents a breakthrough is soft tissue reconstruction.

It has multiple applications in nerve, tendon and bone repair which have been demonstrated as having superior clinical performance when compared to current market leading product.

CelGro nerve repair market opportunity.

Addressable market opportunities

CelGro has significant global commercial potential in its existing addressable markets as well as much wider applications in general surgical and soft tissue reconstruction applications.

Nerve regeneration has a US$7.5 billion addressable market, tendon and ligaments have a US$1.4 billion addressable market and bone regeneration has a US$1 billion addressable market.

The company is also executing a strategy to engage a global partner to manage the distribution and marketing of CelGro for dental bone and soft tissue repair procedures.

In addition, the company has identified that there has been very little innovation in the biologics membrane market resulting in a lack of product differentiation which represents an addressable market of more than US$1 billion per annum.

Pathway to US market

Orthocell has achieved initial EU approval for the product and with the safety and efficiency of the CelGro nerve repair product established, the company is now focused on executing its regulatory program to gain approval in the US.

The company is focused on the US 510(k) study which aims to support an evaluation of substantial equivalence to an approved nerve repair device (meeting the requirements of the US 510(k) predicate product regulatory pathway).

The US FDA pre-submission meeting has been completed, and ethics approval granted.

Surgical procedures will commence in quarter four 2020 with the target for the final data read out of quarter four 2021.

The addressable market for Ortho-ATI is estimated at greater than US$7.7 billion per annum.

Ortho-ATI® therapy

The Ortho-ATI cell therapy for tendon regeneration is an injectable clinical stage cellular therapy for treatment of chronic tendon injuries. It can be utilised at multiple tendon sites including shoulder, elbow, hip, hamstring and achilles.

The therapy addressed an unmet clinical need for a safe, effective, and non-surgical option and is the first injectable cellular therapy in orthopaedics for tendon regeneration.

Ortho-ATI also has extensive clinical validation with more than 690 patients treated to date.

Multiple addressable markets

Ortho-ATI is at the forefront of a large and growing market opportunity where the addressable market is estimated to be greater than US$7.7 billion per annum.

This included tennis elbow (greater than US$4.3 billion and 1,000,000 procedures per annum), Rotator cuff (greater than US$4.4 billion and 530,000 procedures per annum) and Gluteal, patellar, hamstring, achilles (greater than US$1 billion).

The company expects to reach these milestones in the near-term.

Completing clinical studies

Orthocell is focused on completing current clinical studies and preparing for US market entry.

The objective of the current study underway is to assess the effectiveness of Autologous Tenocyte Injection (Ortho-ATI) compared to corticosteroid injection in the treatment of rotator cuff tendinopathy and tear.

This trial is being undertaken in collaboration with DePuy Synthes Products, Inc, part of the Johnson & Johnson Medical Device Companies.

Commercially viable products

The company is confident that its Good Manufatcuring Practice certificate and Therapeutic Goods Administration licensed manufacturing facility underpin its competitive advantage and can be readily scaled to meet market demand.

In addition, Orthocell’s regenerative medicine manufacturing technologies, products and treatment processes patent

Quick facts: Orthocell Ltd

Price: 0.535 AUD

Market: ASX
Market Cap: $100.99 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...


Orthocell's Paul Anderson hails FDA approval for dental bone and tissue...

Orthocell Ltd's (ASX:OCC) Paul Anderson caught up with Proactive's Andrew Scott soon after announcing they've received Food and Drug Administration’s (FDA) 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US....

1 week, 6 days ago

4 min read